On 27 June 2016, orphan designation (EU/3/16/1672) was granted by the European Commission to Celgene Europe Limited, United Kingdom, for 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride (also known as CC-122) for the treatment of diffuse large B-cell lymphoma.
The sponsorship was transferred to Celgene Europe B.V., The Netherlands, in January 2019.
EU/3/16/1672: Public summary of opinion on orphan designation: 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride for the treatment of diffuse large B-cell lymphoma (PDF/126.45 KB)
First published: 26/07/2016
Last updated: 26/07/2016
|Disease / condition||
Treatment of diffuse large B-cell lymphoma
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.